Membranous expression of ectodomain isoforms of the epidermal growth factor receptor predicts outcome after chemoradiotherapy of lymph node-negative cervical cancer

Clinical Cancer Research

Volumn 17, Issue 16, 2011, Pages 5501-5512

  Halle, Cathinka ^a   Lando, Malin ^a   Svendsrud, Debbie Hege ^a   Clancy, Trevor ^b   Holden, Marit ^c   Sundfør, Kolbein ^b   Kristensen, Gunnar B ^b   Holm, Ruth ^a   Lyng, Heidi ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Department of Tumor Biology ^*  (Norway)

^c NORWEGIAN COMPUTING CENTER   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOPROTEIN; MAX PROTEIN; MYC PROTEIN; PROTEIN TYROSINE KINASE;

ADULT; AGED; ARTICLE; AUTOPHOSPHORYLATION; CARCINOGENESIS; CHEMORADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL MEMBRANE; CHEMORADIOTHERAPY; COHORT STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPH NODES; MIDDLE AGED; PHOSPHORYLATION; PROGNOSIS; PROTEIN ISOFORMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 80051685783     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0297     Document Type: Article

References (50)

1. Ngan HY, Cheung AN, Liu SS, Cheng DK, Ng TY, Wong LC. Abnormal expression of epidermal growth factor receptor and c-erbB2 in squamous cell carcinoma of the cervix: correlation with human papillomavirus and prognosis. Tumour Biol 2001;22:176-183 (Pubitemid 32245414)
2. Yamashita H, Murakami N, Asari T, Okuma K, Ohtomo K, Nakagawa K. Correlation among six biologic factors (p53, p21(WAF1), MIB-1, EGFR, HER2, and Bcl-2) and clinical outcomes after curative chemoradiation therapy in squamous cell cervical cancer. Int J Radiat Oncol Biol Phys 2009;74:1165-1172
3. Cannistra SA, Bast RC Jr, Berek JS, Bookman MA, Crum CP, DePriest PD, et al. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol 2003;21:129-132
4. Herrera FG, Vidal L, Oza A, Milosevic M, Fyles A. Molecular targeted agents combined with chemo-radiation in the treatment of locally advanced cervix cancer. Rev Recent Clin Trials 2008;3:111-120
5. West CM, Joseph L, Bhana S. Epidermal growth factor receptor-targeted therapy. Br J Radiol 2008;81:s36-s44
6. Gaffney DK, Haslam D, Tsodikov A, Hammond E, Seaman J, Holden J, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:922-928 (Pubitemid 36794022)
7. Kim YT, Park SW, Kim JW. Correlation between expression of EGFR and the prognosis of patients with cervical carcinoma. Gynecol Oncol 2002;87:84-89 (Pubitemid 36027106)
8. Lee CM, Shrieve DC, Zempolich KA, Lee RJ, Hammond E, Handrahan DL, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol 2005;99:415-421 (Pubitemid 41502854)
9. Noordhuis MG, Eijsink JJ, Ten Hoor KA, Roossink F, Hollema H, Arts HJ, et al. Expression of epidermal growth factor receptor (EGFR) and activated EGFR predict poor response to (chemo)radiation and survival in cervical cancer. Clin Cancer Res 2009;15:7389-7397
10. Fuchs I, Vorsteher N, Buhler H, Evers K, Sehouli J, Schaller G, et al. The prognostic significance of human epidermal growth factor receptor correlations in squamous cell cervical carcinoma. Anticancer Res 2007;27:959-963 (Pubitemid 46587006)
11. Nieto Y, Nawaz F, Jones RB, Shpall EJ, Nawaz S. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. J Clin Oncol 2007;25:4405-4413 (Pubitemid 350013846)
12. Rego RL, Foster NR, Smyrk TC, Le M, O'Connell MJ, Sargent DJ, et al. Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status. Br J Cancer 2010;102:165-172
13. Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 2008;118:3574-3581
14. Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 2010;7:493-507.
15. Wells A. EGF receptor. Int J Biochem Cell Biol 1999;31:637-643 (Pubitemid 29248872)
16. Zandi R, Larsen AB, Andersen P, Stockhausen MT, Poulsen HS. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007;19:2013-2023 (Pubitemid 47353811)
17. Arias-Pulido H, Joste N, Chavez A, Muller CY, Dai D, Smith HO, et al. Absence of epidermal growth factor receptor mutations in cervical cancer. Int J Gynecol Cancer 2008;18:749-754 (Pubitemid 352020185)
18. Normanno N, De LA, Bianco C, Strizzi L, Mancino M, Maiello MR, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16. (Pubitemid 43199589)
19. Sanderson MP, Keller S, Alonso A, Riedle S, Dempsey PJ, Altevogt P. Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J Cell Biochem 2008;103:1783-1797 (Pubitemid 351501910)
20. Perez-Torres M, Valle BL, Maihle NJ, Negron-Vega L, Nieves-Alicea R, Cora EM. Shedding of epidermal growth factor receptor is a regulated process that occurs with overexpression in malignant cells. Exp Cell Res 2008;314:2907-2918
21. Reiter JL, Maihle NJ. Characterization and expression of novel 60-kDa and 110-kDa EGFR isoforms in human placenta. Ann N Y Acad Sci 2003;995:39-47. (Pubitemid 36706612)
22. Basu A, Raghunath M, Bishayee S, Das M. Inhibition of tyrosine kinase activity of the epidermal growth factor (EGF) receptor by a truncated receptor form that binds to EGF: role for interreceptor interaction in kinase regulation. Mol Cell Biol 1989;9:671-677 (Pubitemid 19038870)
23. Flickinger TW, Maihle NJ, Kung HJ. An alternatively processed mRNA from the avian c-erbB gene encodes a soluble, truncated form of the receptor that can block ligand-dependent transformation. Mol Cell Biol 1992;12:883-893
24. Weihua Z, Tsan R, Huang WC, Wu Q, Chiu CH, Fidler IJ, et al. Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 2008;13:385-393 (Pubitemid 351609444)
25. Li Z, Chang Z, Chiao LJ, Kang Y, Xia Q, Zhu C, et al. TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation. Cancer Res 2009;69:7851-7859
26. Senapati S, Das S, Batra SK. Mucin-interacting proteins: from function to therapeutics. Trends Biochem Sci 2010;35:236-245
27. Jarvius M, Paulsson J, Weibrecht I, Leuchowius KJ, Andersson AC, Wahlby C, et al. In situ detection of phosphorylated platelet-derived growth factor receptor beta using a generalized proximity ligation method. Mol Cell Proteomics 2007;6:1500-1509 (Pubitemid 47506163)
28. Halle C, Lando M, Sundfør K, Kristensen GB, Holm R, Lyng H. Phosphorylation of EGFR measured with in situ proximity ligation assay: Relationship to EGFR protein level and gene dosage in cervical cancer. Radiother Oncol 2011 Jun 14. [Epub ahead of print].
29. van Persijn van Meerten EL, Gelderblom H, Bloem JL. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol 2010;20:1456-1467
30. Lyng H, Brovig RS, Svendsrud DH, Holm R, Kaalhus O, Knutstad K, et al. Gene expressions and copy numbers associated with metastatic phenotypes of uterine cervical cancer. BMC Genomics 2006;7:268.
31. Albitar L, Pickett G, Morgan M, Wilken JA, Maihle NJ, Leslie KK. EGFR isoforms and gene regulation in human endometrial cancer cells. Mol Cancer 2010;9:166.
32. Lando M, Holden M, Bergersen LC, Svendsrud DH, Stokke T, Sundfor K, et al. Gene dosage, expression, and ontology analysis identifies driver genes in the carcinogenesis and chemoradioresistance of cervical cancer. PLoS Genet 2009;5:e1000719.
33. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004;3:article 3.
34. Kerrien S, am-Faruque Y, Aranda B, Bancarz I, Bridge A, Derow C, et al. IntAct - open source resource for molecular interaction data. Nucleic Acids Res 2007;35:D561-D565
35. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, et al. Human Protein Reference Database - 2009 update. Nucleic Acids Res 2009;37:D767-D772
36. Stark C, Breitkreutz BJ, Reguly T, Boucher L, Breitkreutz A, Tyers M. BioGRID: a general repository for interaction datasets. Nucleic Acids Res 2006;34:D535-D539
37. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-2504 (Pubitemid 37428274)
38. Dang CV, Le A, Gao P. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 2009;15:6479-6483
39. Hellberg D, Tot T, Stendahl U. Pitfalls in immunohistochemical validation of tumor marker expression-exemplified in invasive cancer of the uterine cervix. Gynecol Oncol 2009;112:235-240
40. Vijayalakshmi N, Selvaluxmi G, Mahji U, Rajkumar T. C-myc oncoprotein expression and prognosis in patients with carcinoma of the cervix: an immunohistochemical study. Eur J Gynaecol Oncol 2002;23:135-138 (Pubitemid 34297117)
41. Swaminathan G, Tsygankov AY. The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol 2006;209:21-43. (Pubitemid 44318665)
42. Cappellen D, De OC, Ricol D, de MS, Bourdin J, Sastre-Garau X, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 1999;23:18-20.
43. Aprelikova O, Pandolfi S, Tackett S, Ferreira M, Salnikow K, Ward Y, et al. Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res 2009;69:616-624
44. Baron AT, Cora EM, Lafky JM, Boardman CH, Buenafe MC, Rademaker A, et al. Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 2003;12:103-113 (Pubitemid 36193999)
45. Fyles A, Milosevic M, Hedley D, Pintilie M, Levin W, Manchul L, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J Clin Oncol 2002;20:680-687 (Pubitemid 34111374)
46. Wilken JA, Baron AT, Maihle NJ. The epidermal growth factor receptor conundrum. Cancer 2010 Dec 14. [Epub ahead of print].
47. Gembitsky DS, Lawlor K, Jacovina A, Yaneva M, Tempst P. A prototype antibody microarray platform to monitor changes in protein tyrosine phosphorylation. Mol Cell Proteomics 2004;3:1102-1118 (Pubitemid 40012103)
48. Sun T, Campbell M, Gordon W, Arlinghaus RB. Preparation and application of antibodies to phosphoamino acid sequences. Biopolymers 2001;60:61-75. (Pubitemid 32601763)
49. Lindstrom AK, Tot T, Stendahl U, Syrjanen S, Syrjanen K, Hellberg D. Discrepancies in expression and prognostic value of tumor markers in adenocarcinoma and squamous cell carcinoma in cervical cancer. Anticancer Res 2009;29:2577-2578
50. Biscardi JS, Maa MC, Tice DA, Cox ME, Leu TH, Parsons SJ. c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function. J Biol Chem 1999;274:8335-8343